Neisseria meningitidis: Pathogenesis and immunity

Current Opinion in Microbiology

Volumn 23, Issue , 2015, Pages 68-72

  Pizza, Mariagrazia ^a   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4CMENB VACCINE; COMPLEMENT FACTOR H; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; COMPLEMENT;

BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTERICIDAL ACTIVITY; CELL ADHESION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; ORGANISMAL INTERACTION; PATHOGENESIS; PROTEIN BINDING; REVIEW; VACCINATION; BACTERIUM ADHERENCE; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SERUM BACTERICIDAL ACTIVITY;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

BACTERIAL ADHESION; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; HOST-PATHOGEN INTERACTIONS; IMMUNE EVASION; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS;

EID: 84918585015     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2014.11.006     Document Type: Review

References (46)

1. Caugant D.A., Maiden M.C. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009, 27:B64-B70.
2. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis: meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
3. Boisier P., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
4. Stein D.M., et al. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine 2006, 24:221-228.
5. Holst J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27:B3-B12.
6. Giuliani M.M., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
7. Martin N.G., Snape M.D. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?. Expert Rev Vaccines 2013, 12:837-858.
8. Richmond P.C., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:597-607.
9. Carbonnelle E., et al. A systematic genetic analysis in Neisseria meningitidis defines the Pil proteins required for assembly: functionality, stabilization and export of Type IV pili. Mol Microbiol 2006, 61:1510-1522.
10. Pelicic V. Type IV pili: e pluribus unum?. Mol Microbiol 2008, 68:827-837.
11. Brown D.R., et al. Systematic functional analysis reveals that a set of seven genes is involved in fine-tuning of the multiple functions mediated by Type IV pili in Neisseria meningitidis. Infect Immun 2010, 78:3053-3063.
12. Coureuil M., et al. Meningococcus Hijacks a beta2-adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010, 143:1149-1160.
13. Lecuyer H., Nassif X., Coureuil M. Two strikingly different signaling pathways are induced by meningococcal Type IV pili on endothelial and epithelial cells. Infect Immun 2012, 80:175-186.
14. Bernard S.C., et al. Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization. Nat Med 2014, 20:725-731.
15. Imhaus A.F., Dumenil G. The number of Neisseria meningitidis Type IV pili determines host cell interaction. EMBO J 2014, 33:1767-1783.
16. Virji M. The structural basis of CEACAM-receptor targeting by neisserial opa proteins: response. Trends Microbiol 2000, 8:260-261.
17. Scarselli M., et al. Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Mol Microbiol 2006, 61:631-644.
18. Sjolinder H., et al. Meningococcal outer membrane protein NhhA is essential for colonization and disease by preventing phagocytosis and complement attack. Infect Immun 2008, 76:5412-5420.
19. Serruto D., et al. Neisseria meningitidis App: a new adhesin with autocatalytic serine protease activity. Mol Microbiol 2003, 48:323-334.
20. Hadi H.A., et al. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol Microbiol 2001, 41:611-623.
21. Comanducci M., et al. NadA: a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195:1445-1454.
22. Fagnocchi L., et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun 2013, 81:560-569.
23. Capecchi B., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55:687-698.
24. Montanari P., et al. Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion. Cell Microbiol 2012, 14:368-385.
25. Malito E, Biancucci M, Faleri A, Ferlenghi I, Scarselli M, Maruggi G, Lo Surdo P, Veggi D, Liguori A, Santini L, Bertoldi I, Petracca R, Marchi S, Romagnoli G, Cartocci E, Vercellino I, Savino S, Spraggon G, Norais N, Pizza M, Rappuoli R, Masignani V, Bottomley MJ: Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A (in press).
26. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
27. Figueroa J.E., Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991, 4:359-395.
28. Lewis L.A., Ram S. Meningococcal disease and the complement system. Virulence 2014, 5:98-126.
29. Masignani V., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
30. Fletcher L.D., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
31. Madico G., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177:501-510.
32. Schneider M.C., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176:7566-7575.
33. Schneider M.C., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
34. Beernink P.T., et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186:3606-3614.
35. Johnson S., et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog 2012, 8:e1002981.
36. van der Veen S., et al. Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun 2014, 82:1157-1163.
37. Costa I., Pajon R., Granoff D.M. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio 2014, 5:e01625-e1714.
38. Lewis L.A., et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 2010, 6:e1001027.
39. Lewis L.A., Carter M., Ram S. The relative roles of factor H binding protein: neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol 2012, 188:5063-5072.
40. Lewis L.A., et al. Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun 2014, 82:2574-2584.
41. Serruto D., et al. Neisseria meningitidis GNA2132: a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107:3770-3775.
42. Agarwal S., et al. Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides. J Immunol 2014, 193:1855-1863.
43. Jarva H., et al. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol 2005, 174:6299-6307.
44. van Ulsen P., et al. A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol 2003, 50:1017-1030.
45. Del Tordello E., et al. Neisseria meningitidis NalP cleaves human complement C3: facilitating degradation of C3b and survival in human serum. Proc Natl Acad Sci U S A 2014, 111:427-432.
46. Loh E., et al. Temperature triggers immune evasion by Neisseria meningitidis. Nature 2013, 502:237-240.